Smoking cessation treatment: Pharmacogenetics assessment

Marcus R. Munafò, Caryn Lerman, Raymond Niaura, Alexandra E. Shields, Gary E. Swan

Research output: Contribution to journalReview articlepeer-review


This review focuses on the current status and future directions of pharmacogenetics research into responses to treatments for nicotine dependence and smoking cessation. Research remains in its infancy and, although the potential for individualized treatment tailored to genotype is promising, there are practical, ethical and social considerations that must be addressed before such research is translated into clinical practice. In particular, future studies that need to be conducted before such research is translated into clinical practice and potential limitations and barriers to this translation are described.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Issue number3
StatePublished - Jun 2005


  • Bupropion
  • Nicotine addiction
  • Nicotine replacement therapy
  • Pharmacogenetics
  • Smoking cessation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)


Dive into the research topics of 'Smoking cessation treatment: Pharmacogenetics assessment'. Together they form a unique fingerprint.

Cite this